Shares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $34.56 indicates a potential upside of 63%.The mean estimate comprises nine short-term price targets with a standard deviation of $10. While the lowest estimate of $12.00 indicates a 43.4% decline from the ...

Shares of Manchester United (MANU) have gained 19.7% over the past four weeks to close the last trading session at $16.99, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21.97 indicates a potential upside of 29.3%.The average comprises three short-term price targets ranging from a low of $16.90 to a high of $26.00, with a standard deviation of $4.64. While the lowest estimate ...

日本央行行长植田和男：基础通胀低于价格目标。 ...

Core Viewpoint - Argenx SE's stock is experiencing a decline due to serious safety concerns raised by the FDA regarding its drug Vyvgart Hytrulo, particularly related to chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) [1][2] Group 1: FDA Concerns - The FDA has identified severe risks associated with Vyvgart Hytrulo, specifically the worsening of CIDP, which is characterized by inflammation of nerve roots and peripheral nerves [1] - The FDA is currently evaluating the need for potential regulatory action regarding Vyvgart [2] Group 2: Drug Approval and Usage - The European Commission has recently approved Vyvgart 1000mg for subcutaneous injection as a monotherapy for adult patients with progressive or relapsing active CIDP after prior treatments [2] - In April, the FDA approved a self-injection option for Vyvgart Hytrulo for adult patients with generalized myasthenia gravis (gMG) and CIDP [3] Group 3: Stock Performance and Analyst Ratings - Argenx's stock has an average 1-year price target of $753.23, indicating an expected upside of 43.52% [4][6] - There are no bearish recommendations for Argenx, with 13 analysts providing bullish ratings; the highest price target is $1065.0 from Guggenheim, while the lowest is $680.0 from Baird [5][7] - As of the latest check, Argenx's stock is down 6.56% at $523.37 [7]

Upbound Group (UPBD) closed the last trading session at $25.48, gaining 11.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $36.63 indicates a 43.8% upside potential.The average comprises eight short-term price targets ranging from a low of $26.00 to a high of $50.00, with a standard deviation of $8.07. While the lowest estimate indicates an increase of 2% from the current price ...

Shares of VNET Group (VNET) have gained 30.7% over the past four weeks to close the last trading session at $6.98, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.29 indicates a potential upside of 76.1%.The mean estimate comprises eight short-term price targets with a standard deviation of $5.54. While the lowest estimate of $5.00 indicates a 28.4% decline from the current ...

Shares of QXO, Inc. (QXO) have gained 21.9% over the past four weeks to close the last trading session at $20.73, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $34.33 indicates a potential upside of 65.6%.The mean estimate comprises three short-term price targets with a standard deviation of $8.74. While the lowest estimate of $27.00 indicates a 30.3% increase from the current ...

Elastic (ESTC) closed the last trading session at $82.69, gaining 2.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $112.17 indicates a 35.7% upside potential.The average comprises 24 short-term price targets ranging from a low of $75.00 to a high of $148.00, with a standard deviation of $15.45. While the lowest estimate indicates a decline of 9.3% from the current price level, ...

Shares of Tsakos Energy (TEN) have gained 12.5% over the past four weeks to close the last trading session at $20.11, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $31 indicates a potential upside of 54.2%.The mean estimate comprises three short-term price targets with a standard deviation of $9.54. While the lowest estimate of $21.00 indicates a 4.4% increase from the current ...

BILL Holdings (BILL) closed the last trading session at $45.28, gaining 0.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $66.75 indicates a 47.4% upside potential.The mean estimate comprises 24 short-term price targets with a standard deviation of $20.19. While the lowest estimate of $40.00 indicates a 11.7% decline from the current price level, the most optimistic analyst expe ...